Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Phase 1 Trial of CD30-Directed, CCR4 Co-Expressing Chimeric Antigen Receptor T-Cells in Patients with CD30 + Cutaneous T-Cell Lymphomas Refractory to Brentuximab Vedotin

Daniel K Reef, Catherine Joyce Arago Cheng, Caroline Babinec, Kelly Hoye, John West, J. Kaitlin Morrison, Faith Brianne Buchanan, Ashley Zanter, Angela Denise Spruill, Kimberly A. Kasow, Anastasia Ivanova, Edith Bowers, Jonathan Serody, Barbara Savoldo, Gianpietro Dotti, Natalie Grover, Anne W Beaven

Blood (2024) 144 (Supplement 1): 3468.

https://doi.org/10.1182/blood-2024-201799

Published: 2024

Journal Articles

CD30.CAR-T Cells Co-Expressing the CCR4 Chemokine Receptor in Relapsed/Refractory Hodgkin Lymphoma

Natalie Grover, Dominic Moore, Anastasia Ivanova, Anne W Beaven, Christopher Dittus, Catherine Joyce Arago Cheng, Kelly Hoye, Caroline Babinec, Faith Brianne Buchanan, Angela Denise Spruill, Ashley Zanter, John West, J. Kaitlin Morrison, Paul Armistead, Kimberly A. Kasow, Jonathan Serody, Gianpietro Dotti, Barbara Savoldo

Blood (2024) 144 (Supplement 1): 919.

https://doi.org/10.1182/blood-2024-200932

Published: 2024

Journal Articles

Azacitidine and Venetoclax with or without Donor Lymphocyte Infusion in Relapsed AML Post Allo-HSCT: A Single-Institution Retrospective Study

Daniel T Peters, Coco Chang, Anson Snow, Kaitlyn M. Buhlinger, Bianka Patel, Taylor Dennison, Stephanie Dawson, Sean Gallagher, Robyn Tolley, Angela Nichols, Daniel R. Richardson, Anastasia Ivanova, Paul Armistead, Joshua F Zeidner

Blood (2024) 144 (Supplement 1): 1481.

https://doi.org/10.1182/blood-2024-193668

Published: 2024

Journal Articles

Abrogation of Immune Effector Cell Neurotoxicity Syndrome (ICANS) By Rimiducid (RIM) in Patients Treated with CD19-Specific Chimeric Antigen Receptor Modified T-Cells (CAR-T) Engineered with an Inducible Caspase 9 (iC9 CAR.19)-Clinical and Pharmacodynamic Correlates

Matthew C. Foster, Barbara Savoldo, Winnie Lau, Clio Rubinos, Natalie S. Grover, Paul M. Armistead, James M. Coghill, Jr., Katarzyna Joanna Jamieson, Robert Hagan, J. Kaitlin Morrison, Faith Brianne Buchanan, Catherine Joyce Arago Cheng, Anastasia Ivanova, Tammy Cavallo, John West, Megan Gonzalez, Jonathan S. Serody, Gianpietro Dotti

Blood (2022) 140 (Supplement 1): 7437–7438.

https://doi.org/10.1182/blood-2022-165558

Published: 2022

Journal Articles

CD30-Directed CAR-T Cells Co-Expressing CCR4 in Relapsed/Refractory Hodgkin Lymphoma and CD30+ Cutaneous T Cell Lymphoma

Natalie S Grover, Anastasia Ivanova, Dominic T. Moore, Catherine Joyce Arago Cheng, Caroline Babinec, John West, Tammy Cavallo, J. Kaitlin Morrison, Faith Brianne Buchanan, Edith Bowers, Christopher Dittus, Anne W. Beaven, Gianpietro Dotti, Jonathan S. Serody, Barbara Savoldo

Blood (2021) 138 (Supplement 1): 742.

https://doi.org/10.1182/blood-2021-148102

Published: 2021

Journal Articles

Utility of a safety switch to abrogate CD19.CAR T-cell–associated neurotoxicity

Matthew C. Foster, Barbara Savoldo, Winnie Lau, Clio Rubinos, Natalie Grover, Paul Armistead, James Coghill, Robert S. Hagan, Kaitlin Morrison, Faith Brianne Buchanan, Catherine Cheng, Spencer Laing, Anastasia Ivanova, John West, Aaron Foster, Jonathan Serody, Gianpietro Dotti

Blood (2021) 137 (23): 3306–3309.

https://doi.org/10.1182/blood.2021010784

Published: 2021

Includes: Supplemental data

Journal Articles

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

Blood (2019) 134 (Supplement_1): 831.

https://doi.org/10.1182/blood-2019-126065

Published: 2019

Journal Articles

ASXL1 / SRSF2 Co-Mutated Acute Myeloid Leukemia (AML): A Rare but Distinct Subpopulation with Dismal Outcomes

Daniel R. Richardson, MD MA, David M Swoboda, MD, Anastasia Ivanova, PhD, Steven M Johnson, MD, Jonathan Galeotti, MD MS, Sonia Esparza, MD, Onyee Chan, MD, Matthew C Foster, MD, Catherine C. Coombs, MD, Nathan D Montgomery, MD, David A Sallman, MD, Joshua F Zeidner, MD

Blood (2019) 134 (Supplement_1): 2598.

https://doi.org/10.1182/blood-2019-122929

Published: 2019

Journal Articles

Genomics Reveal Potential Biomarkers of Response to Pembrolizumab after High Dose Cytarabine in an Ongoing Phase II Trial in Relapsed/Refractory AML

Blood (2018) 132 (Supplement 1): 4054.

https://doi.org/10.1182/blood-2018-99-116608

Published: 2018

Journal Articles

Clinical Responses to CAR.CD30-T Cells in Patients with CD30+ Lymphomas Relapsed after Multiple Treatments Including Brentuximab Vedotin

Blood (2018) 132 (Supplement 1): 681.

https://doi.org/10.1182/blood-2018-99-113534

Published: 2018

Journal Articles

Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML)

Joshua F Zeidner, MD, Benjamin G. Vincent, MD, Anastasia Ivanova, PhD, Matthew Foster, Catherine C. Coombs, MD, Katarzyna Jamieson, MD, Hendrik Van Deventer, MD, Richard Scibilia, Laura Blanchard, Cassiopeia Frank, Sean Gallagher, Melissa Matson, AGPCNP-BC, Katherine Pepin, Lori Vaught, Nancy Vogler, Ivana Gojo, MD, Leo Luznik, MD, Jonathan S Serody, MD

Blood (2017) 130 (Supplement 1): 1349.

https://doi.org/10.1182/blood.V130.Suppl_1.1349.1349

Published: 2017

Journal Articles

A Dose-Finding Study of Lenalidomide As Post-Remission Therapy for Older Adults with Acute Myeloid Leukemia (AML)

Matthew C. Foster, MD, Hendrik W. Van Deventer, MD, Katarzyna Jamieson, MD, Benjamin G. Vincent, MD, Melissa Matson, AGPCNP-BC, Karen McKinnon, PhD, Shannon Reisdorf, BS, Jack Zhang, RN, Will Pulley, BA, Hyman Muss, MD, Anastasia Ivanova, PhD, Joshua F Zeidner, MD

Blood (2017) 130 (Supplement 1): 2631.

https://doi.org/10.1182/blood.V130.Suppl_1.2631.2631

Published: 2017

Journal Articles

Reduced Intensity Continuous Infusion Busulfan for Allogeneic Hematopoietic Cell Transplant Patients with Hematologic Disorders Who Are Ineligible or Inappropriate for Treatment with a More Intensive Therapeutic Regimen: LCCC 0306

Reed Friend, MD, James Xenakis, Jonathan S Serody, MD, Terrance Comeau, MD, Don A. Gabriel, MD PhD, Stefanie Sarantopoulos, MD PhD, James Coghill, MD, William A. Wood, MD MPH, Andrew Sharf, Julia S Whitley, BS, Kamakshi Rao, PharmD, Christine M Walko, PharmD,BCOP, Anastasia Ivanova, PhD, Thomas C. Shea, MD, Paul M Armistead, MD PhD

Blood (2015) 126 (23): 3117.

https://doi.org/10.1182/blood.V126.23.3117.3117

Published: 2015

Journal Articles

A Multicenter Phase II Study Of Bendamustine In Combination With Rituximab In Older Patients With Previously Untreated Diffuse Large B-Cell Lymphoma

Steven I. Park, MD, Kristy L. Richards, MD PhD, Adam S. Asch, MD, Oludamilola Olajide, MBBS, Allison M. Deal, MS, Anastasia Ivanova, PhD, James G. Wall, MD, Anna L. Sobol, MD, Matthew C. Foster, MD, Hyman B. Muss, MD, Thomas C. Shea, M.D.

Blood (2013) 122 (21): 1791.

https://doi.org/10.1182/blood.V122.21.1791.1791

Published: 2013

Journal Articles

Beneficial Effect of Escalated Doses of Busulfan (BU) Delivered by Targeted Pharmacokinetics and Prolonged Continuous Infusion on Relapse Free and Overall Survival in Matched Related and Unrelated Allogeneic Transplant Patients with Hematologic Malignancies

Thomas C. Shea, MD, Christine Walko, PharmD, Anastasia Ivanova, PhD, Julia Whitley, BS, Kamakshi Rao, PharmD, Don A. Gabriel, MD, PhD, Terrance Comeau, MD, FRCPC, James Coghill, MD, Paul M Armistead, MD, PhD, Stefanie Sarantopoulos, MD, PhD, William A. Wood, MD, MPH, Jonathan Serody, MD

Blood (2011) 118 (21): 1940.

https://doi.org/10.1182/blood.V118.21.1940.1940

Published: 2011

Journal Articles

A Phase I, Dose Escalation Study of Clofarabine in Combination with Fractionated Gemtuzumab Ozogamicin in Relapsed and Refractory Acute Myeloid Leukemia (AML).

C Foster Matthew, MD, Chirag Amin, MD, Peter M Voorhees, MD, Hendrik W. Van Deventer, MD, Kristy L. Richards, PhD, MD, Anastasia Ivanova, Jennifer Whitman, RN, BSN, Thomas C. Shea, MD

Blood (2009) 114 (22): 2048.

https://doi.org/10.1182/blood.V114.22.2048.2048

Published: 2009

Journal Articles

Adhesion Molecule Blockade with the Humanized Anti-LFA-1 Monoclonal Antibody Efalizumab Improves Steroid Refractory Acute and Chronic Graft-Versus-Host Disease of the Skin

James M. Coghill, MD, Kristine E. Nograles, MD, James G. Krueger, MD, PhD, Amy S. Coghill, RN, MSN, Jonathan S. Serody, MD, PhD, Anastasia Ivanova, PhD, Julia Whitley, BS, Donald Gabriel, MD, PhD, Terrance Comeau, MD, Thomas Shea, MD

Blood (2008) 112 (11): 4350.

https://doi.org/10.1182/blood.V112.11.4350.4350

Published: 2008

Journal Articles

A Phase I Study of Bortezomib (Velcade ® ) Plus 90 yttrium Labeled Ibritumomab Tiuxetan (Zevalin ® ) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (NHL)

Anne Beaven, MD, Thomas C. Shea, MD, Dominic T Moore, PhD, Tatyana Feldman, MD, Anastasia Ivanova, PhD, Madlyn Ferraro, RN, OCN, CCRC, Peggy Ford, RN, Judy Smith, RN, Andre Goy, MD

Blood (2008) 112 (11): 4944.

https://doi.org/10.1182/blood.V112.11.4944.4944

Published: 2008

Journal Articles

Low Incidence of GVHD and Treatment-Related Morbidity (TRM) with Intermediate Doses of Continuous Infusion IV Busulfan and Daily Fludarabine with Individualized Doses of Alemtuzamab for Matched Related (MRD) and Unrelated (MUD) Transplant Pts with High-Risk Hematologic Malignancies.

Thomas Shea, MD, Jonathan Serody, MD, PhD, Don Gabriel, MD, PhD, Terrance Comeau, MD, Anastasia Ivanova, PhD, Dominic Moore, PhD, Robert Irons, PA, Whitley Julia, BS, Sharf Andrew, RN, Cherie Dunphy, MD, Brecher Mark, MD

Blood (2007) 110 (11): 4940.

https://doi.org/10.1182/blood.V110.11.4940.4940

Published: 2007

Journal Articles

The Association between Serum Copper and Anemia in the Adult NHANES II Population.

Istvan Molnar, MD, Dora Il’yasova, PhD, Anastasia Ivanova, PhD, Mary A. Knovich, MD

Blood (2005) 106 (11): 3766.

https://doi.org/10.1182/blood.V106.11.3766.3766

Published: 2005

NARROW

Phase 1 Trial of CD30-Directed, CCR4 Co-Expressing Chimeric Antigen Receptor T-Cells in Patients with CD30 + Cutaneous T-Cell Lymphomas Refractory to Brentuximab Vedotin

CD30.CAR-T Cells Co-Expressing the CCR4 Chemokine Receptor in Relapsed/Refractory Hodgkin Lymphoma

Azacitidine and Venetoclax with or without Donor Lymphocyte Infusion in Relapsed AML Post Allo-HSCT: A Single-Institution Retrospective Study

Abrogation of Immune Effector Cell Neurotoxicity Syndrome (ICANS) By Rimiducid (RIM) in Patients Treated with CD19-Specific Chimeric Antigen Receptor Modified T-Cells (CAR-T) Engineered with an Inducible Caspase 9 (iC9 CAR.19)-Clinical and Pharmacodynamic Correlates

CD30-Directed CAR-T Cells Co-Expressing CCR4 in Relapsed/Refractory Hodgkin Lymphoma and CD30+ Cutaneous T Cell Lymphoma

Utility of a safety switch to abrogate CD19.CAR T-cell–associated neurotoxicity

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

ASXL1 / SRSF2 Co-Mutated Acute Myeloid Leukemia (AML): A Rare but Distinct Subpopulation with Dismal Outcomes

Genomics Reveal Potential Biomarkers of Response to Pembrolizumab after High Dose Cytarabine in an Ongoing Phase II Trial in Relapsed/Refractory AML

Clinical Responses to CAR.CD30-T Cells in Patients with CD30+ Lymphomas Relapsed after Multiple Treatments Including Brentuximab Vedotin

Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML)

A Dose-Finding Study of Lenalidomide As Post-Remission Therapy for Older Adults with Acute Myeloid Leukemia (AML)

Reduced Intensity Continuous Infusion Busulfan for Allogeneic Hematopoietic Cell Transplant Patients with Hematologic Disorders Who Are Ineligible or Inappropriate for Treatment with a More Intensive Therapeutic Regimen: LCCC 0306

A Multicenter Phase II Study Of Bendamustine In Combination With Rituximab In Older Patients With Previously Untreated Diffuse Large B-Cell Lymphoma

Beneficial Effect of Escalated Doses of Busulfan (BU) Delivered by Targeted Pharmacokinetics and Prolonged Continuous Infusion on Relapse Free and Overall Survival in Matched Related and Unrelated Allogeneic Transplant Patients with Hematologic Malignancies

A Phase I, Dose Escalation Study of Clofarabine in Combination with Fractionated Gemtuzumab Ozogamicin in Relapsed and Refractory Acute Myeloid Leukemia (AML).

Adhesion Molecule Blockade with the Humanized Anti-LFA-1 Monoclonal Antibody Efalizumab Improves Steroid Refractory Acute and Chronic Graft-Versus-Host Disease of the Skin

A Phase I Study of Bortezomib (Velcade ® ) Plus 90 yttrium Labeled Ibritumomab Tiuxetan (Zevalin ® ) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (NHL)

Low Incidence of GVHD and Treatment-Related Morbidity (TRM) with Intermediate Doses of Continuous Infusion IV Busulfan and Daily Fludarabine with Individualized Doses of Alemtuzamab for Matched Related (MRD) and Unrelated (MUD) Transplant Pts with High-Risk Hematologic Malignancies.

The Association between Serum Copper and Anemia in the Adult NHANES II Population.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only